Werewolf Therapeutics, Inc. (HOWL): Nasdaq/NYSE listing notice — Board member Dr. Alon Lazarus dies; Werewolf Therapeutics non-compliant with Nasdaq audit committee rule

Werewolf Therapeutics, Inc.

Dr. Alon Lazarus, board member since Aug 2019, passed away on Sep 30, 2025.
His death reduced the Audit Committee to two members, violating Nasdaq Rule 5605(c)(2) requiring three members.
Company notified Nasdaq on Oct 2, 2025; cure period runs until next annual meeting or Sep 30, 2026.
Board plans to appoint an additional independent director to fill the Audit Committee vacancy.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Werewolf Therapeutics, Inc. received a nasdaq noncompliance notice notice (rules 5605(c)(2), 5605(c)(4)(B)).

Exchange: nasdaq
Notice: noncompliance notice
Rules: 5605(c)(2), 5605(c)(4)(B)

Exact text from the filing

October 2, 2025, the Company notified Nasdaq of the resulting non-compliance with Nasdaq listing rules caused by Dr. Lazarus’s passing. Pursuant to Nasdaq Listing Rule 5605(c)(4)(B), the Company is entitled to a cure period to regain compliance with Nasdaq Listing Rule 5605(c)(2), which cure period will expire upon the earlier of the Company’s next annual meeting of stockholders or September 30, 2026. The Company also informed Nasdaq that the Board plans to regain compliance with the listing rules at its earliest opportunity by appointing an additional independent director of the Company to fi

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Werewolf Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-231953

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.